Dear Label_Name,

Greetings! I hope you are well.

I am writing on behalf of an international publishing house, Science and Education Publishing, USA (http://www.sciepub.com).

Science and Education Publishing (SciEP) is a multidisciplinary open access publisher of Journals covering the fields of Science, Technology and Medicine. All SciEP publications are subject to high-quality peer review, editorial and production processes and are freely available online.

Welcome to the April, 2013 edition of SciEP newsletter, providing monthly summaries of articles on science & education related topics of interest to scientist and professionals. The mission of our journals is to provide an open access forum for publishing new findings on issues pertinent to scientific and academic field. We also invite you to submit original research papers, review articles, short reports, or case studies are considered for publication in our Multidisciplinary Journals.

American Journal of Public Health Research
DOI: 10.12691/ajphr-1-1-3

The Implementation of a Tele-Homecare System with Service Oriented Architecture and HL7 Message Transmission Standard
Ching-Sung Wang

American Journal of Medical and Biological Research
DOI: 10.12691/ajmbr-1-1-2

The Influence of Ethanol on Pyruvate Kinases Activity in Vivo, in Vitro, in Silico
Lelevich Sergey Vladimirovich, Khrustalev Vladislav Victorovich, Barkovsky Eugene Victorovich, Shedogubova Tatyana Aleksandrovna

American Journal of Medical Sciences and Medicine
DOI: 10.12691/ajmsm-1-1-1

Clinical and Histological Features in Wegener Granulomatosis
Li Cavoli Gioacchino, Passantino Rita, Bono Luisa, Tortorici Calogera, Ferrantelli Angelo, Giammarresi Carlo, Rotolo Ugo

American Journal of Infectious Diseases and Microbiology
DOI: 10.12691/ajidm-1-1-2

The Curse of Lymphatic Filariasis: Would the Continual Use of Diethylcarbamazine Eliminate this Scourge in Papua New Guinea?
Anne Lanham, Lillian Mwanri

We have released issues of some journals on February 2013.
American Journal of Public Health Research
American Journal of Medical Sciences and Medicine
American Journal of Medical and Biological Research
American Journal of Pharmacological Sciences
American Journal of Clinical Medicine Research
American Journal of Nursing Research
American Journal of Cancer Prevention
American Journal of Medicine Studies
American Journal of Infectious Diseases and Microbiology
American Journal of Cardiovascular Disease Research
American Journal of Biomedical Research
American Journal of Mechanical Engineering
American Journal of Microbiological Research
Journal of Preventive Medicine
American Journal of Food and Nutrition
American Journal of Hypertension Research
American Journal of Sports Science and Medicine
Journal of Cancer Research and Treatment
American Journal of Zoological Research
Journal of Biomedical Engineering and Technology
American Journal of Microbiological Research
Biomedical Science and Engineering

We are pleased to announce that submissions are now being accepted for peer review for all the journals across all our subject areas in SciEP.

Please submit your manuscript via our online submission system:
http://www.sciepub.com/author/signin

To unsubscribe from our mailing list, please click on the following link: unsubscribe

I am looking forward to hearing from you.

Kind regards,

David Rain
Email:join@sciepub.com
Science and Education Publishing (http://www.sciepub.com)

Late Presentation of SLE and Secondary Anti-phospholipid Syndrome, Following Initial Evans Syndrome

Geetha Wickrematilake

Department of Rheumatology, District General Hospital, Nuwara Eliya, Sri Lanka

Abstract: Background: Evans syndrome associated with secondary anti-phospholipid syndrome has not been reported in case studies and we report a case of SLE and secondary anti-phospholipid syndrome diagnosed seven years after the initial diagnosis of Evans syndrome. Case presentation: A 21-years-old female was diagnosed with Evans syndrome since the age of 14 years, and was on treatment for seven years. At the onset of disease her immunological screening for ANA, Ds-DNA were negative. She was treated with immunosuppressants and steroids and the disease was complicated with Cryptococcal meningitis. Seven years later at the age of 21 years she started to have joint arthritis, and the ANA test converted to positive together with a positive Ds-DNA. Later on she had a single episode of unprovoked deep vein thrombosis in a leg (below knee), and became positive for lupus anticoagulant and IgM anticardiolipin antibodies. Her cardiac imaging (Echo-cardiogram) revealed that she had developed moderate pulmonary hypertension. She was treated with physiotherapy, Methotrexate, Hydroxychloroquine, Warfarin and Sildenafil with good control of the disease. Her lupus is in remission with treatment with no anaemia. Conclusion: Haematological manifestations of systemic lupus erythematosus could vary. Hence, Lupus should be kept in mind always during management of complicated hematological conditions as the patient might fulfill cumulative SLE classification criteria over time.

Keywords: systemic lupus erythematosus, anti-phospholipid syndrome, Evans syndrome, anti-nuclear antibody, haemolytic anaemia

Citation: Geetha Wickrematilake, Late Presentation of SLE and Secondary Anti-phospholipid Syndrome, Following Initial Evans Syndrome. American Journal of Medical Case Reports, 5 (9). 252-253. January 2017. doi:10.12691/ajmcr-5-9-7

1. Introduction

Evans syndrome (ES) is a rare hematological disease characterized by the simultaneous or sequential occurrence of autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) [1]. A significant number of patients also have neutropenia [2]. This syndrome can be classiﬁed as primary when there is no associated disease and secondary when it is associated with other autoimmune diseases such as systemic lupus erythematosus (SLE), primary anti-phospholipid syndrome, Sjögren syndrome, IgA deﬁciency, Hodgkin’s disease and chronic lymphocytic leukemia [3].

Studies have showed that ES seems to be a rare manifestation in SLE and 3% to 15% ES patients would develop SLE during the follow-up [4]. The median interval between presentation of ES and the diagnosis of SLE was 37 months (range 1-76) [5]. However, AIHA appeared simultaneously at the beginning of SLE in the majority [6].

We report a patient who developed SLE and secondary anti-phospholipid syndrome seven years later following the initial diagnosis of ES-showing a varied late presentation of SLE and secondary anti-phospholipid syndrome.

2. Case Report

At the age of 14 years, this patient had presented to the hospital with fever, severe anaemia (Hb=2.4g/dl), total leukocyte count 2.5 × 10 9 /L (Polymorphs-36%) and thrombocytopenia (16,000/L). She had haemolysis with elevated indirect bilirubin and LDH. The direct coombs test (DAT) was positive with cold-acting-AIHA. At that time, her anti-nuclear antibody (ANA) test and anti-phospholipid (aPL) antibody screen were negative. Her septic screen was normal. The erythrocyte sedimentation rate(ESR) by Westergren method was 98 mm /first hour. Corrected reticulocyte count was 5%.

On peripheral blood examination the smear showed marked agglutination of red blood cells, spherocytes and few nucleated red blood cells. The presence of Cold AIHA together with thrombocytopenia lead to the diagnosis of Evans syndrome(ES) and she was started on Steroids (prednisolone 1mg/kg) and immunosuppressant-Azathiprine. With this treatment, patient had frequent relapses of haemolysis as the steroid dose was tailed off- hence had been on prednisolone doses frequently.

At the age of 17 years patient was brought back to the hospital due to an altered level of consciousness, fever and an associated neck stiffness. There were no rashes and this was not accompanied by hemolysis. Her brain CT scan was normal with positive CSF analysis for Cryptococcal meningitis. The HIV screening was negative. Patient was treated with amphotericin B and Flucytosine therapy for 2 weeks followed by fluconazole for 10 weeks with good recovery.

Later on her prednisolone dose was stopped due to good control of the Evans picture and was put on Azathioprine only. At this point her Echo-cardiogram was normal with good ejection fraction. Patient was only managed with Azathioprine for four years until she presented with an unprovoked episode of below knee DVT, episodes of arthritis and shortness of breath on exertion. However, ANA had become positive by this time with coarse speckled pattern at a ratio of ≥1/320, with positive DsDNA levels (150 IU/mL, normal range 35-55 IU/mL).

With history of hemolytic anaemia, arthritis, and with positive immunology screen she was diagnosed as a patient with SLE. Her rheumatoid factor was positive (64iu/l-normal <8iu/l), with negative anti-cyclic citrullinated peptide (anti-CCP). The complement C4 was low 9mg/dl (20-50mg/dl) with normal C3 levels. Complement C3/C4 are often depressed in patients with active SLE as a result of consumption by immune complex–induced inflammation. Her immunoglobulins showed mild elevation in IgM fraction only (363 mg/dl, normal 47-147mg/dl) and had normal serum protein electrophoresis. Serum protein electrophoresis was arranged as this patient with ES had elevated IgM immunoglobulin and these could associate lymphomas.

Her lupus anticoagulant became positive for aPTT, DRVVT with positive anticardiolipin IgM levels- repeated twice 12 weeks apart. The repeat echocardiogram revealed moderate pulmonary hypertension. The Ro/La antibodies, chest imagine were normal.

Patient was switched on to Methotrexate, Hydroxychloroquine, warfarin and Sildenafil with good control of the SLE, and was started on Alendronate due to long term steroid use.

3. Discussion

Since the diagnosis of ES the patient had been on steroids and Azathioprine which has predisposed her to the development of Cryptococcal meningitis. The diagnosis of SLE was confirmed with history of haemolytic anaemia, arthritis, positive ANA and Ds DNA tests.

Thrombocytopenia in SLE patients can be caused by anti-phospholipid syndrome. Thrombocytopenia is evident in 30-40% of patients with anti-phospholipid syndrome [7].

Management and outcome is different in primary and secondary ES and rarely splenectomy may be required for primary Evans syndrome with persistently low platelet count, whereas this may not be necessary in autoimmune diseases like SLE. Drugs reported being used in the treatment of refractory AIHA in SLE include IVIG, Azathioprine and other immunosuppressive medications as well as Danazol and Rituximab. Rituximab therapy is safe and efficacious inducing long-term clinical remission [8].

Our patient responded well to management with methotrexate and hydroxychloroquine therapy for SLE without needing additional immunosuppression.

4. Conclusion

SLE classification criteria are cumulative over time. Hematological complications are very common in SLE. Hence, patients with hematological complications should be kept under strict surveillance as they could develop SLE even after a long time as in this patient.

References

[1]   | Dhingra KK, Jain D, Mandal S, et al. Evans syndrome: a study of six cases with review of literature. Hematology 2008; 13: 356-360.
[2]   | Savasan S, Warrier I, Ravindranath Y. The spectrum of Evans’ syndrome. Arch Dis Child 1997; 77: 245-8
[3]   | Savasan S, Warrier I, Ravindranath Y. The Spectrum of Evan’s syndrome. Arch Dis Child. 1997; 77(3): 245-8.
[4]   | Karpatkin S. Autoimmune thrombocytopenic purpura. Blood 1980; 56: 329-343.
[5]   | Michel M, Chanet V, Dechartres A. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood 2009 114: 3167-3172.
[6]   | Costallat GL, Appenzeller S, Costallat LT. Evans syndrome and systemic lupus erythematosus: clinical presentation and outcome. Joint Bone Spine. 2012 Jul; 79(4): 362-4.
[7]   | Asherson RA. Antiphospholipid antibodies and syndromes. In: Lahita RG, ed. Systemic lupus erythematosus. 2 nd ed. New York: Churchill Livingstone; 1992. p. 612-3.
[8]   | Kumar S, Benseler SM, Kirby-Allen M, et al. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus. Pediatrics 2009; 123: e159-63.